首页> 美国卫生研究院文献>Heliyon >Hemocompatibility and safety of the Carmat Total Artifical Heart hybrid membrane
【2h】

Hemocompatibility and safety of the Carmat Total Artifical Heart hybrid membrane

机译:Carmat全人工心脏混合膜的血液相容性和安全性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The Carmat bioprosthetic total artificial heart (C-TAH) is a biventricular pump developed to minimize drawbacks of current mechanical assist devices and improve quality of life during support. This study aims to evaluate the safety of the hybrid membrane, which plays a pivotal role in this artificial heart. We investigated in particular its blood-contacting surface layer of bovine pericardial tissue, in terms of mechanical aging, risks of calcification, and impact of the hemodynamics shear stress inside the ventricles on blood components. Hybrid membranes were aged in a custom-designed endurance bench. Mechanical, physical and chemical properties were not significantly modified from 9 months up to 4 years of aging using a simulating process. Exploration of erosion areas did not show no risk of oil diffusion through the membrane. Blood contacting materials in the ventricular cavities were subcutaneously implanted in Wistar rats for 30 days as a model for calcification and demonstrated that the in-house anti-calcification pretreatment with Formaldehyde-Ethanol-Tween 80 was able to significantly reduce the calcium concentration from 132 μg/mg to 4.42 μg/mg (p < 0.001). Hemodynamic simulations with a computational model were used to reproduce shear stress in left and right ventricles and no significant stress was able to trigger hemolysis, platelet activation nor degradation of the von Willebrand factor multimers. Moreover, explanted hybrid membranes from patients included in the feasibility clinical study were analyzed confirming preclinical results with the absence of significant membrane calcification. At last, blood plasma bank analysis from the four patients implanted with C-TAH during the feasibility study showed no residual glutaraldehyde increase in plasma and confirmed hemodynamic simulation-based results with the absence of hemolysis and platelet activation associated with normal levels of plasma free hemoglobin and platelet microparticles after C-TAH implantation. These results on mechanical aging, calcification model and hemodynamic simulations predicted the safety of the hybrid membrane used in the C-TAH, and were confirmed in the feasibility study.
机译:Carmat生物假体全人工心脏(C-TAH)是一种双心室泵,其开发目的是最大程度地减少当前机械辅助设备的弊端并改善支持期间的生活质量。这项研究旨在评估混合膜的安全性,该膜在该人造心脏中起关键作用。我们特别研究了牛心包组织的血液接触表面层,包括机械老化,钙化风险以及脑室内血流动力学剪切应力对血液成分的影响。混合膜在定制的耐久试验台上老化。使用模拟过程,从9个月到4年的老化,机械,物理和化学特性没有明显改变。勘探侵蚀区域并没有显示出油通过膜扩散的风险。将心室腔中的血液接触材料皮下植入Wistar大鼠中30天,作为钙化模型,证明甲醛-乙醇-吐温80进行的室内抗钙化预处理能够将钙浓度从132μg显着降低/ mg至4.42μg/ mg(p <0.001)。使用具有计算模型的血流动力学模拟来再现左心室和右心室中的切应力,并且没有明显的应力能够触发溶血,血小板活化或von Willebrand因子多聚体的降解。此外,对可行性临床研究中包括的患者移植的混合膜进行了分析,以确认临床前结果,而没有明显的膜钙化。最后,在可行性研究期间对四名植入C-TAH的患者进行血浆库分析表明,血浆中残留的戊二醛没有增加,并证实了基于血液动力学模拟的结果,没有溶血和血小板活化,血浆游离血红蛋白水平正常C-TAH植入后的血小板和血小板微粒。这些有关机械老化,钙化模型和血液动力学模拟的结果预测了C-TAH中使用的杂化膜的安全性,并在可行性研究中得到了证实。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号